Morphological and functional changes of islets of Langerhans in FK506-treated rats.
FK506, a new immunosuppressant, caused glucose intolerance in rats given daily oral doses of 1, 5, or 10 mg/kg/day for 14 days, but did not induce hyperglycemia under normal feeding. Besides the glucose intolerance, insulin secretion was impaired and insulin levels in the pancreas were lowered. Histopathologically, there was vacuolation of the Langerhans islets in the animals given 10 mg/kg. After withdrawal of the drug, these changes in pancreatic function and morphology returned to normal within 2 weeks. The findings indicate that FK506 caused dose-dependent but reversible islet toxicity in rats.
Hirano
Y
Y
Toxicology Research Laboratories, Fujisawa Pharmaceutical Company, Osaka, Japan.
Fujihira
S
S
Ohara
K
K
Katsuki
S
S
Noguchi
H
H
D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D001835:Body Weight / Q000187:drug effects; D004435:Eating / Q000187:drug effects; D007328:Insulin / Q000097:blood; D007515:Islets of Langerhans / Q000187:drug effects* / Q000473:pathology / Q000502:physiology; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D016559:Tacrolimus / Q000633:toxicity*
D001786:Blood Glucose; D007328:Insulin; D016559:Tacrolimus